INFI Insider Trading Activity and SEC Form 4 Filings
INFI insider trading summary
No open-market insider purchases or sales of Infinity Pharmaceuticals, Inc. (INFI) have been reported on SEC Form 4 in the past 12 months.
Latest INFI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 12, 2023 | Adelene Q Perkins | Director | Sell | $29K (410,196 @ $0.07) |
| Aug 2, 2022 | Stephane Peluso | Chief Scientific Officer | Sell | $10K (14,994 @ $0.66) |
| Feb 11, 2021 | Bvf Gp Holdings LLC | 10% Owner | Sell | $6.5M (1,215,491 @ $5.37) |
| Feb 11, 2021 | Biotechnology Value Fund L P | Insider | Sell | $6.5M (1,215,491 @ $5.37) |
| Feb 11, 2021 | Bvf II Gp LLC | Insider | Sell | $6.5M (1,215,491 @ $5.37) |
| Feb 11, 2021 | BVF Partners OS Ltd. | Insider | Sell | $6.5M (1,215,491 @ $5.37) |
| Feb 11, 2021 | Bvf I Gp LLC | Insider | Sell | $6.5M (1,215,491 @ $5.37) |
| Feb 11, 2021 | Biotechnology Value Trading Fund OS LP | Insider | Sell | $6.5M (1,215,491 @ $5.37) |
| Feb 11, 2021 | Bvf Partners L P/Il | 10% Owner | Sell | $6.5M (1,215,491 @ $5.37) |
| Feb 11, 2021 | Bvf Inc/Il | 10% Owner | Sell | $6.5M (1,215,491 @ $5.37) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.